The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy...
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults...
HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, has announced a multi-year agreement with Eli Lilly and Company...